BioRestorative Therapies (BRTX) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 11, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,571,678
Trading Symbol	BRTX
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash	$ 1,891	$ 31,822
Accounts receivable	20,000	6,000
Prepaid expenses and other current assets	24,660	35,578
Total Current Assets	46,551	73,400
Property and equipment, net	416,556	508,594
Intangible assets, net	926,397	963,845
Security deposit	34,176	34,176
Total Assets	1,423,680	1,580,015
Current Liabilities:
Accounts payable	2,466,839	2,283,981
Accrued expenses and other current liabilities	1,895,907	1,574,659
Accrued interest	198,111	127,375
Current portion of notes payable, net of debt discount of $99,768 and $152,720 at June 30, 2017 and December 31, 2016, respectively	2,433,331	1,858,845
Total Current Liabilities	6,994,188	5,844,860
Accrued expenses, non-current portion	17,697	430,000
Accrued interest, non-current portion	6,719	7,681
Notes payable, non-current portion, net of debt discount of $843 and $27,244 at June 30, 2017 and December 31, 2016, respectively	120,120	297,756
Total Liabilities	7,138,724	6,580,297
Commitments and contingencies
Stockholders’ Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued and outstanding 5,491,605 and 4,699,035 shares at June 30, 2017 and December 31, 2016, respectively	5,491	4,699
Additional paid-in capital	41,772,200	36,954,817
Accumulated deficit	(47,492,735)	(41,959,798)
Total Stockholders’ Deficiency	(5,715,044)	(5,000,282)
Total Liabilities and Stockholders’ Deficiency	$ 1,423,680	$ 1,580,015

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 99,768	$ 152,720
Notes payable non-current, debt discount	$ 843	$ 27,244
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares Issued	5,491,605	4,699,035
Common stock, shares Outstanding	5,491,605	4,699,035

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues	$ 20,000	$ 16,155	$ 27,000	$ 25,280
Cost of sales		71		81
Gross Profit	20,000	16,084	27,000	25,199
Operating Expenses
Marketing and promotion	9,053	18,178	38,123	40,695
Consulting	875,309	550,006	1,339,444	834,813
Research and development	610,725	608,688	1,416,578	1,474,732
General and administrative	1,093,928	982,358	2,291,241	1,885,239
Total Operating Expenses	2,589,015	2,159,230	5,085,386	4,235,479
Loss From Operations	(2,569,015)	(2,143,146)	(5,058,386)	(4,210,280)
Other Expense
Interest expense	(95,403)	(45,008)	(193,204)	(87,848)
Amortization of debt discount	(84,167)	(65,448)	(216,909)	(402,469)
Gain (loss) on extinguishment of notes payable, net	1,402	(4,813)	(59,938)	(16,660)
Warrant modification expense			(4,500)	(28,486)
Total Other Expense	(178,168)	(115,269)	(474,551)	(535,463)
Net Loss	$ (2,747,183)	$ (2,258,415)	$ (5,532,937)	$ (4,745,743)
Net Loss Per Share - Basic and Diluted	$ (0.51)	$ (0.56)	$ (1.06)	$ (1.26)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	5,401,864	4,006,617	5,196,300	3,776,207

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Common Stock [Member]
Balance		$ 4,699
Balance, shares		4,699,035
Shares and warrants issued for cash		$ 331
Shares and warrants issued for cash, shares		331,335
Exercise of warrants for purchase of common stock		$ 50
Exercise of warrants for purchase of common stock, shares		50,000
Conversion of notes payable and accrued interest into common stock		$ 104
Conversion of notes payable and accrued interest into common stock, shares		104,632
Shares and warrants issued in exchange of notes payable and accrued interest		$ 132
Shares and warrants issued in exchange of notes payable and accrued interest, shares		132,082
Shares and warrants issued in satisfaction of accrued services		$ 157
Shares and warrants issued in satisfaction of accrued services, shares		156,668
Shares and warrants issued or modified and recorded as debt discount in connection with notes payable		$ 18
Shares and warrants issued or modified and recorded as debt discount in connection with notes payable,shares		17,853
Beneficial conversion features related to convertible notes payable
Warrant modifications
Stock-based compensation: - options and warrants
Net loss
Balance	$ 5,491	$ 5,491
Balance, shares	5,491,605	5,491,605
Additional Paid-In Capital [Member]
Balance		$ 36,954,817
Shares and warrants issued for cash		993,669
Exercise of warrants for purchase of common stock		174,950
Conversion of notes payable and accrued interest into common stock		246,030
Shares and warrants issued in exchange of notes payable and accrued interest		421,170
Shares and warrants issued in satisfaction of accrued services		568,547
Shares and warrants issued or modified and recorded as debt discount in connection with notes payable		124,999
Beneficial conversion features related to convertible notes payable		407
Warrant modifications		4,500
Stock-based compensation: - options and warrants		2,283,111
Net loss
Balance	$ 41,772,200	41,772,200
Accumulated Deficit [Member]
Balance		(41,959,798)
Shares and warrants issued for cash
Exercise of warrants for purchase of common stock
Conversion of notes payable and accrued interest into common stock
Shares and warrants issued in exchange of notes payable and accrued interest
Shares and warrants issued in satisfaction of accrued services
Shares and warrants issued or modified and recorded as debt discount in connection with notes payable
Beneficial conversion features related to convertible notes payable
Warrant modifications
Stock-based compensation: - options and warrants
Net loss		(5,532,937)
Balance	(47,492,735)	(47,492,735)
Balance		(5,000,282)
Shares and warrants issued for cash		$ 994,000
Shares and warrants issued for cash, shares		331,335
Exercise of warrants for purchase of common stock		$ 175,000
Conversion of notes payable and accrued interest into common stock		246,134
Shares and warrants issued in exchange of notes payable and accrued interest		421,302
Shares and warrants issued in satisfaction of accrued services		568,704
Shares and warrants issued or modified and recorded as debt discount in connection with notes payable		125,017
Beneficial conversion features related to convertible notes payable		407
Warrant modifications		4,500
Stock-based compensation: - options and warrants		2,283,111
Net loss	(2,747,183)	(5,532,937)
Balance	$ (5,715,044)	$ (5,715,044)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows From Operating Activities
Net loss	$ (5,532,937)	$ (4,745,743)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	216,909	402,469
Accretion of interest expense	89,365	2,916
Depreciation and amortization	129,486	127,182
Stock-based compensation	2,283,111	1,355,327
Loss on extinguishment of note payables, net	59,938	16,660
Loss on settlement of payables	98,704
Warrant modification expense	4,500	28,486
Changes in operating assets and liabilities:
Accounts receivable	(14,000)	77,375
Prepaid expenses and other current assets	10,918	15,326
Accounts payable	215,555	(377,197)
Accrued interest, expenses and other current liabilities	453,524	361,794
Total Adjustments	3,548,009	2,010,338
Net Cash Used In Operating Activities	(1,984,928)	(2,735,405)
Cash Flows From Investing Activities
Purchases of property and equipment		(151,200)
Net Cash Used In Investing Activities		(151,200)
Cash Flows From Financing Activities
Proceeds from notes payable	875,000	980,000
Repayments of notes payable	(74,003)	(118,500)
Advances from an officer	34,015	89,045
Repayments of advances from an officer and a director	(49,015)	(160,575)
Proceeds from exercise of warrants	175,000	212,898
Sales of common stock and warrants for cash	994,000	2,233,372
Net Cash Provided By Financing Activities	1,954,997	3,236,240
Net (Decrease) Increase In Cash	(29,931)	349,635
Cash - Beginning	31,822	166,555
Cash - Ending	1,891	516,190
Supplemental Disclosures of Cash Flow Information:
Interest	11,000	15,000
Non-cash investing and financing activities:
Warrants modification expense	4,500
Shares and warrants issued or modified as debt discount in connection with notes payable	125,017	129,613
Shares and warrants issued in exchange for notes payable and accrued interest	421,302	231,480
Conversion of notes payable and accrued interest into common stock	246,134	215,158
Shares issued in satisfaction of accrued consulting and director services	568,704	27,553
Beneficial conversion features recorded as debt discount	$ 407	$ 215,446

Business Organization and Natur

Business Organization and Nature of Operations	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). Stem Cell Cayman Ltd. (“Cayman”), which was formed in the Cayman Islands as a wholly-owned subsidiary of the Company, was dissolved during the three months ended March 31, 2017. BioRestorative Therapies, Inc. and its subsidiaries are referred to collectively as “BRT” or the “Company” (See Note 3 – Summary of Significant Accounting Policies – Principles of Consolidation). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com BRTX-100 in vitro The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2017 and for the three and six months ended June 30, 2017 and 2016. The results of operations for the six months ended June 30, 2017 are not necessarily indicative of the operating results for the full year ending December 31, 2017 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2016 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 22, 2017.

Going Concern and Management's

Going Concern and Management's Plans	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2 – Going Concern and Management’s Plans As of June 30, 2017, the Company had a working capital deficiency and a stockholders’ deficiency of $6,947,637 and $5,715,044, respectively. During the three and six months ended June 30, 2017, the Company incurred net losses of $2,747,183 and $5,532,937, respectively. These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern within the twelve months from the filing date of this report. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. Subsequent to June 30, 2017, the Company has received aggregate debt proceeds of $250,000, debt and accrued interest of $120,963 and $7,006, respectively, has been converted into or exchanged for common stock, and the due date for the repayment of $1,007,250 of debt has been extended to dates between October 2017 and February 2018. As a result, the Company expects to have the cash required to fund its operations through September 2017. While there can be no assurance that it will be successful, the Company is in negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $382,500 which are past due. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 8 – Subsequent Events for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. As discussed above, Cayman, which had no material assets, liabilities or operations (other than intercompany balances) and is no longer needed to facilitate certain financings, was dissolved in March 2017. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Concentrations One license and the related royalties comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2017. See Revenue Recognition below. Revenue Recognition The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three and six months ended June 30, 2017, the Company did not recognize revenue related to sales of Stem Pearls skincare products. During the three and six months ended June 30, 2016, the Company recognized revenue related to sales of Stem Pearls skincare products of $155 and $280, respectively. In November 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the three and six months ended June 30, 2017, the Company recognized $20,000 and $27,000, respectively, of revenue related to the Company’s sublicense agreement. During the three and six months ended June 30, 2016, the Company recognized $16,000 and $25,000, respectively, of revenue related to the Company’s sublicense agreement. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2017 2016 Options 3,018,700 2,160,950 Warrants 3,592,831 2,486,286 Convertible notes 276,943 90,297 Total potentially dilutive shares 6,888,474 4,737,533 Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) are registered, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In May 2017, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation—Stock Compensation (Topic 718)” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 31, 2019 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating the effect that adopting this new accounting guidance will have on its consolidated cash flows and related disclosures.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2017
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: June 30, 2017 December 31, 2016 Credit card payable $ 1,369 $ 1,778 Accrued payroll 970,748 1,105,293 Accrued research and development expenses 486,177 581,175 Accrued general and administrative expenses 407,681 263,468 Deferred rent 47,629 52,945 Total accrued expenses $ 1,913,604 $ 2,004,659 During the six months ended June 30, 2017, the Company received non-interest bearing advances in the amount of $34,015 from an officer of the Company and repaid an aggregate of $49,015 of non-interest bearing advances from a director and an officer of the Company. Effective March 1, 2017, the Company entered into an exchange agreement with the Chairman of the Company’s Scientific Advisory Board, pursuant to which an aggregate of $175,000 of accrued consulting fees were exchanged for 58,334 shares of common stock of the Company and, in consideration thereof, the Company issued to such person an immediately vested five-year warrant for the purchase of 58,334 shares of common stock of the Company at an exercise price of $4.00 per share. The common stock and warrants had an aggregate grant date value of $211,752 and, as a result, the Company recorded a loss on settlement of payables of $36,752. Effective March 1, 2017, the Company entered into exchange agreements with four non-employee directors of the Company, pursuant to which an aggregate of $265,000 of accrued director fees were exchanged for an aggregate of 88,334 shares of common stock of the Company and, in consideration thereof, the Company issued to the directors immediately vested five-year warrants for the purchase of an aggregate of 88,334 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate value of the shares and warrants was $320,652, and accordingly the Company recorded a loss on settlement of payables of $55,652. See Note 6 – Commitments and Contingencies – Consulting Agreements for details regarding an additional exchange of accrued consulting fees for shares of common stock and warrants.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Notes Payable	Note 5 – Notes Payable A summary of the notes payable activity during the six months ended June 30, 2017 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2016 $ 697,500 $ 390,000 [1] $ 1,249,065 $ (179,964 ) $ 2,156,601 Issuances - 350,000 618,000 - 968,000 Exchanges for equity (97,500 ) (50,000 ) (203,750 ) - (351,250 ) Conversions to equity - (233,750 ) - - (233,750 ) Repayments (50,000 ) - (24,003 ) - (74,003 ) Recognition of debt discount - - - (218,420 ) (218,420 ) Accretion of interest expense - - 8,500 80,864 89,364 Amortization of debt discount - - - 216,909 216,909 Outstanding, June 30, 2017 $ 550,000 $ 456,250 [1] $ 1,647,812 $ (100,611 ) $ 2,553,451 [1] As of June 30, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $456,250 and $390,000, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $343,750 and $296,250 of principal into shares of common stock at June 30, 2017 and December 31, 2016, respectively, at the same conversion price. Related Party Notes As of June 30, 2017 and December 31, 2016, related party notes consisted of notes payable issued to certain directors of the Company and the Tuxis Trust (the “Trust”). A director and principal shareholder of the Company serves as the trustee of Trust, which was established for the benefit of his immediate family. During the six months ended June 30, 2017, the Company and certain related party lenders agreed to exchange certain related party notes with an aggregate principal balance of $97,500 and aggregate accrued interest of $288 into an aggregate of 32,597 shares of common stock and immediately vested five-year warrants to purchase an aggregate of 32,597 shares of common stock at an exercise price of $4.00 per share. The common stock and warrants had an aggregate exchange date value of $118,328 and, as a result, the Company recorded a loss on extinguishment of notes payable of $20,540. During the six months ended June 30, 2017, the Company repaid an aggregate principal amount of $50,000 of related party notes. Convertible Notes During the six months ended June 30, 2017, the Company issued lenders convertible notes in the aggregate principal amount of $350,000, which bear interest at a rate of 10% per annum payable at maturity. The convertible notes mature between dates in November 2017 to February 2018. Each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to between 50% to 60% of the fair market value of the Company’s stock, depending on the particular convertible note; however, in no event shall the conversion price be less than a price between $0.75 to $1.00 per share, depending on the particular convertible note. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price. The Company will recognize the beneficial conversion feature of the note as debt discount at the time the contingently adjustable conversion ratio is resolved. In connection with the issuance of these convertible notes, the Company issued a certain lender 8,000 shares of common stock and a certain other lender a five-year warrant to purchase 7,500 shares of common stock at an exercise price of $4.00 per share. The aggregate relative fair value of the common stock and warrants of $24,388 was recorded as an original issue discount and is being amortized over the terms of the respective notes. During the six months ended June 30, 2017, the Company and a certain lender agreed to exchange a certain convertible note with a principal balance of $50,000 and accrued interest of $2,712 into 29,280 shares of common stock. The common stock had an exchange date value of $58,560 and, as a result, the Company recorded a loss on extinguishment of notes payable of $5,848. During the six months ended June 30, 2017, the Company elected to convert certain convertible notes with an aggregate principal balance of $233,750 and aggregate accrued interest of $12,384 into an aggregate of 104,632 shares of common stock at conversion prices ranging from $1.96 to $2.77 per share. Other Notes During the six months ended June 30, 2017, the Company issued lenders other notes in the aggregate principal amount of $618,000 for aggregate gross proceeds of $525,000, and the difference of $93,000 has been recorded as an original issue discount and will be amortized over the terms of the respective notes. The other notes bear interest at rates between 0% to 10% per annum payable at maturity. The other notes matured or mature between dates in May 2017 to December 2017. In connection with the issuance of these other notes, the Company issued a certain lender 7,353 shares of common stock and certain other lenders five-year warrants to purchase an aggregate of 40,000 shares of common stock at an exercise price of $4.00 per share. The aggregate relative fair value of the common stock and warrants of $68,688 was recorded as an original issue discount and is being amortized over the terms of the respective notes. During the six months ended June 30, 2017, the Company and certain lenders agreed to exchange certain other notes with an aggregate principal balance of $203,750 and aggregate accrued interest of $7,114 into an aggregate of 70,205 shares of common stock and immediately vested five-year warrants to purchase an aggregate of 63,205 shares of common stock at an exercise price of $4.00 per share. In addition, in consideration of the exchange by certain lenders, the Company agreed to extend the expiration dates of certain warrants held by the lenders for the purchase of an aggregate of 18,000 shares of common stock of the Company at an exercise price of $4.00 per share, from expiration dates ranging from April 27, 2021 to January 31, 2022 to a new expiration date of February 8, 2022. The common stock, warrants, and warrant modification (which represents the incremental value of the modified warrant as compared to the original warrant value, both valued as of the modification date) had an aggregate exchange date value of $244,414 and, as a result, the Company recorded a loss on extinguishment of notes payable of $33,550. During the six months ended June 30, 2017, the Company and certain lenders agreed to extend other notes with an aggregate principal balance of $572,000, that were near or at maturity, to various dates through October 2017. In connection with one of the extensions, the Company issued the lender 2,500 shares of common stock. The issuance date fair value of the common stock of $5,000 has been recorded as a debt discount and is being amortized over the term of the note. In connection with the extensions, the Company issued certain lenders five-year, immediately vested warrants to purchase an aggregate of 18,000 shares of common stock at exercise prices ranging between $4.00 to $5.00 per share. The aggregate grant date fair value of the warrants of $26,940 has been recorded as debt discount and is being amortized over the term of the note. Additionally, in connection with one of the extensions, the Company incurred an extension fee in the amount $8,500 which was accreted as interest expense and added to the principal balance of the note. During the six months ended June 30, 2017, the Company repaid an aggregate principal amount of $24,003 of other notes.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Consulting Agreements Business Advisory Services In March 2017, a previously expired agreement for business advisory services was further amended. Pursuant to the amendment, the agreement was reinstated effective as of January 1, 2017 and provides for an expiration date of December 31, 2017. In consideration of the extension of the term of the consulting agreement, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 25,000 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate grant date value of the warrant of $40,763 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. Concurrently, the Company entered into an exchange agreement with the consultant pursuant to which $30,000 of accrued consulting fees were exchanged for 10,000 shares of common stock of the Company and, in consideration thereof, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 10,000 shares of common stock of the Company at an exercise price of $4.00 per share. The aggregate value of shares and warrant was $36,300, and accordingly the Company recorded a loss on settlement of payables of $6,300. Operating Lease Rent expense amounted to approximately $31,000 and $63,000 for the three and six months ended June 30, 2017, respectively. During the three and six months ended June 30, 2016, the Company recognized approximately $33,000 and $66,000, respectively, of rent expense. Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business, and as of June 30, 2017, none are expected to materially impact the Company’s financial position. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements In February 2017 and March 2017, the Company’s Compensation Committee and Board of Directors, respectively, approved the following associated with performance-based cash bonuses for certain of the Company’s officers and current employees: (i) new performance-based cash bonuses payable for the year ending December 31, 2017 such that an aggregate of up to $402,500 could be earned for such year pursuant to the satisfaction of such goals; and (ii) the amendment of the performance-based cash bonuses for the year ended December 31, 2016 such that an aggregate of up to $322,000 could be earned for such year pursuant to the satisfaction of such goals. Also, pursuant to the amendment of the performance-based cash bonuses, the Company’s officers and certain employees’ achievement date of 2016 milestones was extended from January 31, 2017 to July 31, 2017. As of December 31, 2016, the Company accrued approximately $191,000 for 2016 bonus milestones which were achieved and approximately $100,000 for 2016 bonus milestones which were probable to be achieved. As of June 30, 2017, the Company accrued approximately $255,250 for 2016 bonus milestones which were achieved and approximately $199,870 for 2017 bonus milestones which were probable to be achieved.

Stockholders' Deficiency

Stockholders' Deficiency	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Common Stock and Warrant Offerings During the six months ended June 30, 2017, the Company issued an aggregate of 331,335 shares of common stock and five-year immediately vested warrants to purchase an aggregate of 341,335 shares of common stock at an exercise price of $4.00 to investors for aggregate gross proceeds of $994,000. The warrants had an aggregate grant date fair value of $553,295. Warrant Compensation On April 5, 2017, the Company extended, a previously expired agreement with a consultant from January 1, 2017 to June 30, 2017. In connection with this extension, the Company issued a five-year immediately vested warrant to purchase 20,000 shares of common stock at an exercise price of $4.50 per share. The warrant grant date fair value of $30,440 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the six months ended June 30, 2017 and 2016. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Warrant Modification and Exercise On February 10, 2017, with respect to a warrant held by an investor, the Company agreed that (i) the conditions to the exercisability of the warrant for tranches to purchase an aggregate of 35,000 shares were eliminated, such that the entire warrant to purchase 50,000 shares of common stock was exercisable, and (ii) the exercise price of the warrant was reduced from an exercise price of $30.00 per share to $3.50 per share. Concurrent with the modification of the warrant, the investor exercised the warrant in full for aggregate gross proceeds to the Company of $175,000. The Company recognized a warrant modification charge of $4,500 during the six months ended June 30, 2017, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates which is reflected in warrant modification expense in the unaudited condensed consolidated statement of operations . Stock Warrants In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Three Months Ended For the Six Months Ended June 30, June 30, 2017 2016 2017 2016 Risk free interest rate 1.98% - 2.22 % 1.01% - 1.41 % 1.98% - 2.33 % 0.44% - 1.47 % Expected term (years) 5.00 5.00 5.00 0.67 - 5.00 Expected volatility 120 % 126 % 120% - 132 % 124% - 126 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2017 was approximately $1.47 and $1.61 per share, respectively. The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2016 was $1.02 and $1.76 per share, respectively. The Company recorded stock–based compensation expense of $30,440 and $71,203 during the three and six months ended June 30, 2017, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the unaudited condensed consolidated statements of operations. As of June 30, 2017, there was no unrecognized stock-based compensation expense related to stock warrants. The Company recorded no stock–based compensation expense during the three and six months ended June 30, 2016. A summary of the warrant activity during the six months ended June 30, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2016 2,953,651 $ 5.40 [1] Issued 704,305 4.03 Exercised (50,000 ) 3.50 Expired (15,125 ) 30.33 Outstanding, June 30, 2017 3,592,831 $ 4.93 3.2 $ - Exercisable, June 30, 2017 3,592,831 $ 4.93 3.2 $ - [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that had an exercise price which was the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability was subject to satisfaction of certain performance criteria which had not occurred as of December 31, 2016. As discussed above under Warrant Modification and Exercise, on February 10, 2017, the performance criteria were eliminated and the exercise price was reduced to $3.50 per share in consideration of the full exercise of the warrant by the holder. The following table presents information related to stock warrants at June 30, 2017: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 2,243,550 3.4 2,243,550 $5.00 - $5.99 1,184,243 3.0 1,184,243 $6.00 - $7.99 40,000 3.1 40,000 $8.00 - $9.99 2,500 2.4 2,500 $10.00 - $14.99 55,446 2.8 55,446 $15.00 - $19.99 38,559 2.2 38,559 $20.00 - $80.00 28,533 0.7 28,533 3,592,831 3.2 3,592,831 Stock Options On February 14, 2017, the Compensation Committee reduced the exercise price of outstanding options for the purchase of an aggregate of 1,219,450 shares of common stock of the Company (with exercise prices ranging between $5.70 and $30.00 per share) to $4.70 per share, which was the closing price for the Company’s common stock on February 13, 2017, as reported by the OTCQB. The exercise price reduction related to options held by, among others, the Company’s executive officers and directors. The incremental value of the modified options compared to the original options, both valued as of the respective modification date, of $430,394 is being recognized over the vesting term of the options. On June 23, 2017, the Company issued ten-year options to an employee and directors to purchase an aggregate of 850,000 shares of common stock at an exercise price of $3.35 per share. The options vest as follows: (i) options for the purchase of 283,336 shares vest immediately, (ii) options for the purchase of 283,334 shares vest on the one year anniversary of the issuance date and (iii) options for the purchase of 283,330 shares vest on the two year anniversary of the issuance date. The options had an aggregate grant date value of $2,391,900. A summary of the option activity during the six months ended June 30, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2016 2,168,950 6.27 Granted 850,000 3.35 Forfeited (250 ) 4.70 Outstanding, June 30, 2017 3,018,700 $ 4.34 8.4 $ - Exercisable, June 30, 2017 1,721,212 $ 4.74 7.8 $ - The following table presents information related to stock options at June 30, 2017: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $3.10 - $3.99 1,707,000 9.3 756,342 $4.00 - $4.99 1,234,200 6.8 887,370 $5.00 - $5.99 5,000 7.0 5,000 $6.00 - $19.99 37,500 6.5 37,500 $20.00 - $30.00 35,000 4.7 35,000 3,018,700 7.8 1,721,212 The following table presents information related to stock option expense: Weighted For the For the Average Three Months Six Months Remaining Ended Ended Amortization June 30, June 30, Unrecognized at Period 2017 2016 2017 2016 June 30, 2017 (Years) Consulting $ 714,545 $ 439,644 $ 983,159 $ 543,742 $ 1,645,293 1.6 Research and development 106,507 75,156 364,923 182,339 609,198 1.6 General and administrative 476,226 442,450 863,826 592,163 1,194,109 1.5 $ 1,297,278 $ 957,250 $ 2,211,908 $ 1,318,244 $ 3,448,600 1.6

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 8 – Subsequent Events Notes Payable Subsequent to June 30, 2017, the Company issued a director and principal shareholder of the Company a note in the principal amount of $175,000 (the “$175,000 Loan”), which bears interest at a rate of 15% per annum payable at maturity. The maturity date of the note is December 1, 2017 (subject to acceleration under certain circumstances). The Company agreed that the payment of the note is secured by the grant of a security interest in the Company’s equipment and intellectual property. Subsequent to June 30, 2017, the Company issued a note in the principal amount of $83,333 of which $58,333 of principal bears interest at 10% per annum and is convertible into common stock. In connection with the issuance of the note, the Company received gross proceeds of $75,000, and the difference of $8,333 has been recorded as an original issue discount and will be amortized over the term of the note. The note is payable as follows: (i) $25,000 of principal, which bears no interest and is not convertible into common stock, is payable three weeks from the issuance date, (ii) $11,667 of principal and the respective interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (iii) $11,667 of principal and the respective interest on such principal is payable two weeks following the First Maturity Date, (iv) $11,667 of principal and the respective accrued interest on such principal is payable four weeks following the First Maturity Date, (v) $11,667 of principal and the respective interest on such principal is payable six weeks following the First Maturity Date, and (vi) $11,667 of principal and the respective interest on such principal is payable eight weeks following the First Maturity Date. Excluding the $25,000 of principal that is not convertible into common stock as described above, each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to 50% of the fair market value of the Company’s stock; however, in no event shall the conversion price be less than $0.75 per share. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price. The Company will recognize the beneficial conversion feature of the note as debt discount at the time the contingently adjustable conversion ratio is resolved. Subsequent to June 30, 2017, the Company elected to convert certain convertible notes with an aggregate principal balance of $120,963 and accrued interest of $7,006 into an aggregate of 68,239 shares of common stock at conversion prices ranging from $1.75 to $1.92 per share. Subsequent to June 30, 2017, the Company and the Trust agreed to extend the maturity date of a note payable with a principal balance of $500,000 from July 1, 2017 to December 1, 2017 (subject to acceleration under certain circumstances). In connection with the note extension, the Company increased the effective rate at which the note bears interest from 10% to 15% effective July 1, 2017. In connection with the $175,000 Loan, the Company agreed that the payment of the note is secured by the grant of a security interest in the Company’s equipment and intellectual property. Subsequent to June 30, 2017, the Company and a lender agreed to extend the maturity dates of notes payable with an aggregate principal balance of $457,250 with maturity dates ranging from July 3, 2017 through July 4, 2017 to maturity dates ranging from October 1, 2017 through October 2, 2017. In connection with the note extensions, the Company increased the effective rate at which the notes bear interest from 0% to 8% effective August 2, 2017. Also, in connection with the note extensions, the Company added a conversion feature, pursuant to which each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the lender any time immediately until the balance has been paid in full at a conversion price equal to 80% of the fair market value of the Company’s stock (subject to reduction to 70% under certain circumstances); however, in no event shall the conversion price be less than $1.00 per share. The Company will recognize the beneficial conversion feature of the note as debt discount at the time the contingently adjustable conversion ratio is resolved. Subsequent to June 30, 2017, the Company and a director of the Company agreed to extend the maturity date of a note payable with a principal balance of $50,000 from February 2017 to February 2018. In connection with the extension, the Company issued the director five-year, immediately vested warrants to purchase 5,000 shares of common stock at an exercise price of $4.00 per share. Warrants Subsequent to June 30, 2017, the Company issued an immediately vested five-year warrant to purchase 25,000 shares of common stock at an exercise price of $4.00 per share to a consultant for services rendered. Options Subsequent to June 30, 2017, the Company issued ten-year options to employees and an advisor to purchase an aggregate of 267,000 shares of common stock at exercise prices ranging between $2.80 to $3.35 per share. The options vest as follows: (i) options for the purchase of 89,004 shares vest on the one year anniversary of the issuance date, (ii) options for the purchase of 89,002 shares vest on the two year anniversary of the issuance date and (iii) options for the purchase of 88,994 shares vest on the three year anniversary of the issuance date. Current Liabilities Subsequent to June 30, 2017, the Company entered into an exchange agreement with a certain vendor of the Company, pursuant to which $17,697 of accounts payable were exchanged for 8,334 shares of common stock of the Company. In consideration thereof, the Company issued to the vendor immediately vested five-year warrants for the purchase of 2,000 shares of common stock of the Company at an exercise price of $4.00 per share.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. As discussed above, Cayman, which had no material assets, liabilities or operations (other than intercompany balances) and is no longer needed to facilitate certain financings, was dissolved in March 2017.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations	Concentrations One license and the related royalties comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2017. See Revenue Recognition below.
Revenue Recognition	Revenue Recognition The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three and six months ended June 30, 2017, the Company did not recognize revenue related to sales of Stem Pearls skincare products. During the three and six months ended June 30, 2016, the Company recognized revenue related to sales of Stem Pearls skincare products of $155 and $280, respectively. In November 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the three and six months ended June 30, 2017, the Company recognized $20,000 and $27,000, respectively, of revenue related to the Company’s sublicense agreement. During the three and six months ended June 30, 2016, the Company recognized $16,000 and $25,000, respectively, of revenue related to the Company’s sublicense agreement.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2017 2016 Options 3,018,700 2,160,950 Warrants 3,592,831 2,486,286 Convertible notes 276,943 90,297 Total potentially dilutive shares 6,888,474 4,737,533
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) are registered, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2017, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation—Stock Compensation (Topic 718)” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 31, 2019 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating the effect that adopting this new accounting guidance will have on its consolidated cash flows and related disclosures.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2017 2016 Options 3,018,700 2,160,950 Warrants 3,592,831 2,486,286 Convertible notes 276,943 90,297 Total potentially dilutive shares 6,888,474 4,737,533

Accrued Expenses and Other Cu17

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: June 30, 2017 December 31, 2016 Credit card payable $ 1,369 $ 1,778 Accrued payroll 970,748 1,105,293 Accrued research and development expenses 486,177 581,175 Accrued general and administrative expenses 407,681 263,468 Deferred rent 47,629 52,945 Total accrued expenses $ 1,913,604 $ 2,004,659

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the six months ended June 30, 2017 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2016 $ 697,500 $ 390,000 [1] $ 1,249,065 $ (179,964 ) $ 2,156,601 Issuances - 350,000 618,000 - 968,000 Exchanges for equity (97,500 ) (50,000 ) (203,750 ) - (351,250 ) Conversions to equity - (233,750 ) - - (233,750 ) Repayments (50,000 ) - (24,003 ) - (74,003 ) Recognition of debt discount - - - (218,420 ) (218,420 ) Accretion of interest expense - - 8,500 80,864 89,364 Amortization of debt discount - - - 216,909 216,909 Outstanding, June 30, 2017 $ 550,000 $ 456,250 [1] $ 1,647,812 $ (100,611 ) $ 2,553,451 [1] As of June 30, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $456,250 and $390,000, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $343,750 and $296,250 of principal into shares of common stock at June 30, 2017 and December 31, 2016, respectively, at the same conversion price.

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Share Based Payment Award Stock Warrants Valuation Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Three Months Ended For the Six Months Ended June 30, June 30, 2017 2016 2017 2016 Risk free interest rate 1.98% - 2.22 % 1.01% - 1.41 % 1.98% - 2.33 % 0.44% - 1.47 % Expected term (years) 5.00 5.00 5.00 0.67 - 5.00 Expected volatility 120 % 126 % 120% - 132 % 124% - 126 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the six months ended June 30, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2016 2,953,651 $ 5.40 [1] Issued 704,305 4.03 Exercised (50,000 ) 3.50 Expired (15,125 ) 30.33 Outstanding, June 30, 2017 3,592,831 $ 4.93 3.2 $ - Exercisable, June 30, 2017 3,592,831 $ 4.93 3.2 $ - [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that had an exercise price which was the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability was subject to satisfaction of certain performance criteria which had not occurred as of December 31, 2016. As discussed above under Warrant Modification and Exercise, on February 10, 2017, the performance criteria were eliminated and the exercise price was reduced to $3.50 per share in consideration of the full exercise of the warrant by the holder.
Schedule of Stock Warrant	The following table presents information related to stock warrants at June 30, 2017: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 2,243,550 3.4 2,243,550 $5.00 - $5.99 1,184,243 3.0 1,184,243 $6.00 - $7.99 40,000 3.1 40,000 $8.00 - $9.99 2,500 2.4 2,500 $10.00 - $14.99 55,446 2.8 55,446 $15.00 - $19.99 38,559 2.2 38,559 $20.00 - $80.00 28,533 0.7 28,533 3,592,831 3.2 3,592,831
Schedule of Stock Option activity	A summary of the option activity during the six months ended June 30, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2016 2,168,950 6.27 Granted 850,000 3.35 Forfeited (250 ) 4.70 Outstanding, June 30, 2017 3,018,700 $ 4.34 8.4 $ - Exercisable, June 30, 2017 1,721,212 $ 4.74 7.8 $ -
Schedule of Stock Option	The following table presents information related to stock options at June 30, 2017: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $3.10 - $3.99 1,707,000 9.3 756,342 $4.00 - $4.99 1,234,200 6.8 887,370 $5.00 - $5.99 5,000 7.0 5,000 $6.00 - $19.99 37,500 6.5 37,500 $20.00 - $30.00 35,000 4.7 35,000 3,018,700 7.8 1,721,212
Information Related to Stock Option Expense	The following table presents information related to stock option expense: Weighted For the For the Average Three Months Six Months Remaining Ended Ended Amortization June 30, June 30, Unrecognized at Period 2017 2016 2017 2016 June 30, 2017 (Years) Consulting $ 714,545 $ 439,644 $ 983,159 $ 543,742 $ 1,645,293 1.6 Research and development 106,507 75,156 364,923 182,339 609,198 1.6 General and administrative 476,226 442,450 863,826 592,163 1,194,109 1.5 $ 1,297,278 $ 957,250 $ 2,211,908 $ 1,318,244 $ 3,448,600 1.6

Going Concern and Management'20

Going Concern and Management's Plans (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficiency	$ 6,947,637		$ 6,947,637
Stockholder's deficiency	5,715,044		5,715,044		$ 5,000,282
Net loss	2,747,183	$ 2,258,415	5,532,937	$ 4,745,743
Proceeds from debt			250,000
Amount of debt			120,963
Accrued interest			7,006
Repayments of debt			1,007,250
Note payable past due	$ 382,500		$ 382,500

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stem Pearls Skincare Products [Member]
Revenues		$ 155		$ 280
Sublicense Agreement [Member]
Deferred revenue recognized	$ 20,000	$ 16,000	$ 27,000	$ 25,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Total potentially dilutive shares	6,888,474	4,737,533
Options [Member]
Total potentially dilutive shares	3,018,700	2,160,950
Warrants [Member]
Total potentially dilutive shares	3,592,831	2,486,286
Convertible Notes [Member]
Total potentially dilutive shares	276,943	90,297

Accrued Expenses and Other Cu23

Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Proceeds from related party notes			$ 34,015	$ 89,045
Repayment of advances from director and officer			$ 49,015	160,575
Warrants to purchase common stock	341,335		341,335
Exercise price per share	$ 4		$ 4
Loss on extinguishment of notes payable, net	$ 1,402	$ (4,813)	$ (59,938)	$ (16,660)
Exchange Agreement[Member]
Debt conversion, converted instrument, shares issued			10,000
Warrants to purchase common stock	10,000		10,000
Exercise price per share	$ 4		$ 4
Common stock and warrants aggregate grant date value			$ 36,300
Loss on extinguishment of notes payable, net			6,300
Exchange Agreement[Member] | Chairman [Member]
Accrued consulting fees	$ 175,000		$ 175,000
Debt conversion, converted instrument, shares issued			58,334
Warrants expiration period			5 years
Warrants to purchase common stock	58,334		58,334
Exercise price per share	$ 4		$ 4
Common stock and warrants aggregate grant date value			$ 211,752
Loss on extinguishment of notes payable, net			$ 36,752
Exchange Agreement[Member] | Four Non-Employee Directors [Member]
Debt conversion, converted instrument, shares issued			88,334
Warrants expiration period			5 years
Warrants to purchase common stock	88,334		88,334
Exercise price per share	$ 4		$ 4
Common stock and warrants aggregate grant date value			$ 320,652
Loss on extinguishment of notes payable, net			55,652
Accrued expenses, non-current portion	$ 265,000		265,000
Non-Interest Bearing Advance [Member]
Proceeds from related party notes			34,015
Repayment of advances from director and officer			$ 49,015

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - Accrued Expenses and Other Current Liabilities [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 1,369	$ 1,778
Accrued payroll	970,748	1,105,293
Accrued research and development expenses	486,177	581,175
Accrued general and administrative expenses	407,681	263,468
Deferred rent	47,629	52,945
Total accrued expenses	$ 1,913,604	$ 2,004,659

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 456,250		$ 456,250		$ 390,000
Warrants to purchase common stock	341,335		341,335
Common stock an exercise price per share	$ 4		$ 4
Loss on extinguishment of note payables, net	$ (1,402)	$ 4,813	$ 59,938	$ 16,660
Repayments of related party debt			$ 49,015	160,575
Number of common stock shares issued			331,335
Fair value of warrant			$ 553,295
Proceeds from issuance of note			875,000	980,000
Original issue discount	99,768		99,768		$ 152,720
Amortization of debt discount	$ 84,167	$ 65,448	216,909	$ 402,469
Repayments of debt			$ 1,007,250
Common Stock [Member]
Debt Instrument [Line Items]
Number of common stock shares issued			331,335
Notes Payable [Member]
Debt Instrument [Line Items]
Repayments of debt			$ 24,003
Minimum [Member] | Lenders Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ .75		$ .75
Maximum [Member] | Lenders Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 1		$ 1
Lenders Convertible Note [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	7,500		7,500
Common stock an exercise price per share	$ 4		$ 4
Number of common stock shares issued			8,000
Fair value of warrant			$ 24,388
Lenders Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 50,000		50,000
Accrued interest	2,712		$ 2,712
Debt conversion, converted instrument, shares issued			29,280
Common stock aggregate exchange date fair value	58,560		$ 58,560
Loss on extinguishment of note payables, net			5,848
Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	233,750		233,750
Accrued interest	$ 12,384		$ 12,384
Debt conversion, converted instrument, shares issued			104,632
Convertible Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 1.96		$ 1.96
Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 2.77		$ 2.77
Lenders Other Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 618,000		$ 618,000
Warrant issued term			5 years
Debt maturity date description			The other notes matured or mature between dates in May 2017 to December 2017.
Number of common stock shares issued			7,353
Proceeds from issuance of note			$ 525,000
Original issue discount	93,000		93,000
Lenders Other Notes [Member] | Common Stock and Warrants [Member]
Debt Instrument [Line Items]
Original issue discount	$ 68,688		$ 68,688
Lenders Other Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	40,000		40,000
Common stock an exercise price per share	$ 4		$ 4
Interest rate	0.00%		0.00%
Lenders Other Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate	10.00%		10.00%
Other Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 203,750		$ 203,750
Accrued interest	$ 7,114		$ 7,114
Debt conversion, converted instrument, shares issued			70,205
Other Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	63,205		63,205
Common stock an exercise price per share	$ 4		$ 4
Lender [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 97,500		$ 97,500
Accrued interest	$ 288		$ 288
Debt conversion, converted instrument, shares issued			32,597
Warrant issued term			5 years
Warrants to purchase common stock	32,597		32,597
Common stock an exercise price per share	$ 4		$ 4
Common stock aggregate exchange date fair value	$ 118,328		$ 118,328
Loss on extinguishment of note payables, net			20,540
Repayments of related party debt			50,000
Lender [Member] | Other Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 572,000		$ 572,000
Warrant issued term			5 years
Warrants to purchase common stock	18,000		18,000
Number of common stock shares issued			2,500
Fair value of warrant			$ 26,940
Amortization of debt discount			$ 5,000
Lender [Member] | Minimum [Member] | Notes Payable [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share	$ 4		$ 4
Lender [Member] | Maximum [Member] | Notes Payable [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share	$ 5		$ 5
Lender [Member] | Lenders Convertible Note [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 350,000		$ 350,000
Accrued interest	$ 7,402		$ 7,402
Interest rate	10.00%		10.00%
Debt maturity date description			The convertible notes mature between dates in November 2017 to February 2018
Lender [Member] | Lenders Convertible Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Conversion price, percentage			50.00%
Lender [Member] | Lenders Convertible Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Conversion price, percentage			60.00%
Lenders [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	18,000		18,000
Common stock an exercise price per share	$ 4		$ 4
Common stock aggregate exchange date fair value	$ 244,414		$ 244,414
Loss on extinguishment of note payables, net			$ 33,550

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Outstanding beginning				$ 2,156,601
Issuances				968,000
Exchanges to equity				(351,250)
Conversion to equity				(233,750)
Repayments				(74,003)	$ (118,500)
Recognition of debt discount				(218,420)
Accretion of interest expense				89,365	2,916
Amortization of debt discount		$ 84,167	$ 65,448	216,909	$ 402,469
Outstanding ending		2,553,451		2,553,451
Debt Discount [Member]
Outstanding beginning				(179,964)
Issuances
Exchanges to equity
Conversion to equity
Repayments
Recognition of debt discount				(218,420)
Accretion of interest expense				80,864
Amortization of debt discount				216,909
Outstanding ending		(100,611)		(100,611)
Convertible Notes Payable [Member]
Outstanding beginning	[1]			390,000
Issuances				350,000
Exchanges to equity				(50,000)
Conversion to equity				(233,750)
Repayments
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Outstanding ending	[1]	456,250		456,250
Other Notes [Member]
Outstanding beginning				1,249,065
Issuances				618,000
Exchanges to equity				(203,750)
Conversion to equity
Repayments				(24,003)
Recognition of debt discount
Accretion of interest expense				8,500
Amortization of debt discount
Outstanding ending		1,647,812		1,647,812
Related Party Notes [Member]
Outstanding beginning				697,500
Issuances
Exchanges to equity				(97,500)
Conversion to equity
Repayments				(50,000)
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Outstanding ending		$ 550,000		$ 550,000
[1]	As of June 30, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $456,250 and $390,000, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $343,750 and $296,250 of principal into shares of common stock at June 30, 2017 and December 31, 2016, respectively, at the same conversion price.

Notes Payable - Schedule of N27

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Debt instrument, face amount	$ 456,250	$ 390,000
Debt conversion, converted instrument, amount	233,750
Maximum [Member]
Debt conversion, converted instrument, amount	$ 343,750	$ 296,250

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Warrant term			5 years
Warrants to purchase common stock	341,335		341,335
Exercise price per share	$ 4		$ 4
Fair value of warrant			$ 553,295
Loss on settlement of notes payable, net	$ 1,402	$ (4,813)	(59,938)	$ (16,660)
Rent expense	31,000	$ 33,000	63,000	$ 66,000
Employment Agreement [Member]
Bonus payments					$ 191,000
Employment Agreement [Member] | 2016 Bonus Milestones Achieved [Member]
Bonus payments			255,250		$ 100,000
Employment Agreement [Member] | 2017 Bonus Milestones Achieved [Member]
Bonus payments			199,870
Employment Agreement [Member] | Maximum [Member] | December 31, 2017 [Member]
Cash bonuses	402,500		402,500
Employment Agreement [Member] | Maximum [Member] | December 31, 2016 [Member]
Cash bonuses	$ 322,000		$ 322,000
February 2011 Agreement[Member]
Agreement expiration date			Dec. 31, 2017
Consulting Agreement [Member]
Warrant term			5 years
Warrants to purchase common stock	25,000		25,000
Exercise price per share	$ 4		$ 4
Fair value of warrant			$ 40,763
Exchange Agreement[Member]
Warrant term			5 years
Warrants to purchase common stock	10,000		10,000
Exercise price per share	$ 4		$ 4
Consulting expense			$ 30,000
Debt conversion, converted instrument, shares issued			10,000
Common stock and warrants aggregate grant date value			$ 36,300
Loss on settlement of notes payable, net			$ 6,300

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Jun. 23, 2017	Apr. 05, 2017	Feb. 14, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Feb. 10, 2017
Number of common stock issued						331,335
Warrant term						5 years
Warrants to purchase common stock				341,335		341,335
Exercise price per share				$ 4		$ 4
Gross proceeds from warrants						$ 994,000
Fair value of warrant						553,295
Warrant modification charge						$ 4,500
Weighted average estimated fair value of the warrants granted				$ 1.47	$ 1.02	$ 1.61	$ 1.76
Stock based compensation expenses						$ 2,283,111	$ 1,355,327
Warrants [Member]
Warrant term		5 years
Warrants to purchase common stock		20,000
Exercise price per share		$ 4.50
Fair value of warrant		$ 30,440
Warrant Modification and Exercise [Member]
Warrants to purchase common stock								50,000
Gross proceeds from warrants						175,000
Stock Warrants [Member]
Stock based compensation expenses				$ 30,440		$ 71,203
Stock Options [Member]
Warrants to purchase common stock	850,000		1,219,450
Exercise price per share	$ 3.35		$ 5.70
Stock options modification value			$ 430,394
Stock option term			10 years
Number of option to purchase shares	283,336
Option grant date fair value	$ 2,391,900
Tranches [Member] | Warrant Modification and Exercise [Member]
Warrants to purchase common stock								35,000
One Year Anniversary [Member] | Stock Options [Member]
Number of option to purchase shares	283,334
Two Year Anniversary [Member] | Stock Options [Member]
Number of option to purchase shares	283,330
Minimum [Member] | Warrant Modification and Exercise [Member]
Exercise price per share								$ 3.50
Minimum [Member] | Stock Options [Member]
Exercise price per share			$ 4.70
Maximum [Member] | Warrant Modification and Exercise [Member]
Exercise price per share								$ 30
Maximum [Member] | Stock Options [Member]
Exercise price per share			$ 30
Warrant And Option Valuation [Member] | Minimum [Member]
Estimated forfeitures related to option grants at an annual rate						0.00%
Warrant And Option Valuation [Member] | Maximum [Member]
Estimated forfeitures related to option grants at an annual rate						5.00%

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Share based Payment Award Warrants Valuation Assumptions (Details) - Warrant [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Expected term (years)	5 years	5 years	5 years
Expected volatility	120.00%	126.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Risk free interest rate	1.98%	1.01%	1.98%	0.44%
Expected term (years)				8 months 2 days
Expected volatility			120.00%	124.00%
Maximum [Member]
Risk free interest rate	2.22%	1.41%	2.33%	1.47%
Expected term (years)				5 years
Expected volatility			132.00%	126.00%

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Number of Warrants Exercisable, Balance | shares	1,721,212
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 6.27
Weighted Average Exercise Price Outstanding, Issued	3.35
Weighted Average Exercise Price Outstanding, Expired	4.70
Weighted Average Exercise Price Outstanding, Ending Balance	4.34
Weighted Average Exercise Price Exercisable, Balance	$ 4.74
Weighted Average Remaining Life In Years Outstanding	8 years 4 months 24 days
Weighted Average Remaining Life In Years Exercisable	7 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $
Warrant [Member]
Number of Warrants Outstanding, Beginning Balance | shares	2,953,651
Number of Warrants Outstanding, Issued | shares	704,305
Number of Warrants Outstanding, Exercised | shares	(50,000)
Number of Warrants Outstanding, Expired | shares	(15,125)
Number of Warrants Outstanding, Ending Balance | shares	3,592,831
Number of Warrants Exercisable, Balance | shares	3,592,831
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 5.40	[1]
Weighted Average Exercise Price Outstanding, Issued	4.03
Weighted Average Exercise Price Outstanding, Exercised	3.50
Weighted Average Exercise Price Outstanding, Expired	30.33
Weighted Average Exercise Price Outstanding, Ending Balance	4.93
Weighted Average Exercise Price Exercisable, Balance	$ 4.93
Weighted Average Remaining Life In Years Outstanding	3 years 2 months 12 days
Weighted Average Remaining Life In Years Exercisable	3 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $
[1]	Excludes the impact of a warrant to purchase 35,000 shares of common stock that had an exercise price which was the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability was subject to satisfaction of certain performance criteria which had not occurred as of December 31, 2016. As discussed above under Warrant Modification and Exercise, on February 10, 2017, the performance criteria were eliminated and the exercise price was reduced to $3.50 per share in consideration of the full exercise of the warrant by the holder.

Stockholders' Deficiency - Su32

Stockholders' Deficiency - Summary of Warrant Activity (Details) (Parenthetical) - $ / shares	Jun. 30, 2017	Feb. 10, 2017
Exercise price per share	$ 4
Warrant Exercises [Member]
Exercise price per share		$ 3.50
Warrant [Member]
Warrants to purchase shares of common stock	35,000
Exercise price per share	$ 30

Stockholders' Deficiency - Sc33

Stockholders' Deficiency - Schedule of Stock Warrant (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,592,831
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	3,592,831
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,243,550
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	2,243,550
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,184,243
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years
Warrants Exercisable, Exercisable Number of Warrants	1,184,243
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	2,500
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	55,446
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	55,446
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	38,559
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	38,559
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	28,533
Warrants Exercisable, Weighted Average Remaining Life In Years	8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	28,533
Minimum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Minimum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5
Minimum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	6
Minimum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	8
Minimum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	10
Minimum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	15
Minimum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	80
Maximum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	4.99
Maximum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5.99
Maximum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	7.99
Maximum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	9.99
Maximum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	14.99
Maximum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	19.99
Maximum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 20

Stockholders' Deficiency - Sc34

Stockholders' Deficiency - Schedule of Stock Option activity (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Equity [Abstract]
Number of Options, Outstanding, beginning | shares	2,168,950
Number of Options, Granted | shares	850,000
Number of Options, Forfeited | shares	(250)
Number of Options, Outstanding, ending | shares	3,018,700
Number of Options, Exercisable | shares	1,721,212
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 6.27
Weighted Average Exercise Price, Granted | $ / shares	3.35
Weighted Average Exercise Price, Forfeited | $ / shares	4.70
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	4.34
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 4.74
Weighted Average Remaining Life In Years Outstanding	8 years 4 months 24 days
Weighted Average Remaining Life In Years Exercisable	7 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $

Stockholders' Deficiency - Sc35

Stockholders' Deficiency - Schedule of Stock Options (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	3,018,700
Options Exercisable, Weighted Average Remaining Life In Years	7 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	1,721,212
Exercise Price One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	1,707,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 3 months 19 days
Options Exercisable, Exercisable Number of Options	756,342
Exercise Price One [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.10
Exercise Price One [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	1,234,200
Options Exercisable, Weighted Average Remaining Life In Years	6 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	887,370
Exercise Price Two [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Two [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years
Options Exercisable, Exercisable Number of Options	5,000
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	37,500
Options Exercisable, Weighted Average Remaining Life In Years	6 years 6 months
Options Exercisable, Exercisable Number of Options	37,500
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	35,000
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 20
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 30

Stockholders' Deficiency - Info

Stockholders' Deficiency - Information Related to Stock Option Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Options [Member]
Unrecognized expense	$ 3,448,600		$ 3,448,600
Option [Member]
Stock-based compensation expense	1,297,278	$ 957,250	$ 2,211,908	$ 1,318,244
Weighted Average Remaining Amortization Period			1 year 7 months 6 days
Consulting [Member] | Options [Member]
Stock-based compensation expense	714,545	439,644	$ 983,159
Weighted Average Remaining Amortization Period			1 year 7 months 6 days
Research and Development Expense [Member] | Options [Member]
Stock-based compensation expense	106,507	75,156	$ 364,923	182,339
Unrecognized expense	609,198		$ 609,198
Weighted Average Remaining Amortization Period			1 year 7 months 6 days
General and Administrative Expense [Member] | Options [Member]
Stock-based compensation expense	476,226	$ 442,450	$ 863,826	592,163
Unrecognized expense	1,194,109		$ 1,194,109
Weighted Average Remaining Amortization Period			1 year 6 months
Consulting Expense [Member] | Options [Member]
Stock-based compensation expense				$ 543,742
Unrecognized expense	$ 1,645,293		$ 1,645,293

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		6 Months Ended	12 Months Ended
		Jun. 30, 2017	Dec. 31, 2016	Jun. 23, 2017	Feb. 14, 2017
Notes payable		$ 2,553,451	$ (2,156,601)
Original issue discount		99,768	152,720
Debt instruments conversion amount		233,750
Aggregate principal amount		$ 456,250	390,000
Warrant exercise price		$ 4
Exchange Agreement[Member]
Debt instruments conversion into shares		10,000
Warrant exercise price		$ 4
Stock Options [Member]
Warrant exercise price				$ 3.35	$ 5.70
Minimum [Member] | Stock Options [Member]
Warrant exercise price					4.70
Maximum [Member]
Debt instruments conversion amount		$ 343,750	296,250
Maximum [Member] | Stock Options [Member]
Warrant exercise price					$ 30
Convertible Notes Payable [Member]
Notes payable	[1]	456,250	$ (390,000)
Debt instruments conversion amount		233,750
Lender [Member]
Aggregate principal amount		97,500
Accrued interest		$ 288
Debt instruments conversion into shares		32,597
Warrant exercise price		$ 4
Lender [Member] | Notes Payable [Member] | Minimum [Member]
Warrant exercise price		4
Lender [Member] | Notes Payable [Member] | Maximum [Member]
Warrant exercise price		$ 5
Subsequent Event [Member]
Debt instruments conversion amount		$ 58,333
Percentage of conversion price equal to fair market value		50.00%
Conversion price per share		$ 0.75
Subsequent Event [Member] | Exchange Agreement[Member]
Warrants vested term		5 years
Warrant to purchase common stock issued in period		2,000
Warrant exercise price		$ 4
Number of common shares exchanged for accounts payable		8,334
Number of common shares exchanged for accounts payable, value		$ 17,697
Subsequent Event [Member] | Employees and Advisor [Member] | Stock Options [Member]
Warrants vested term		10 years
Warrant to purchase common stock issued in period		267,000
Subsequent Event [Member] | Employees and Advisor [Member] | Stock Options [Member] | One Year Anniversary [Member]
Warrant to purchase common stock issued in period		89,004
Subsequent Event [Member] | Employees and Advisor [Member] | Stock Options [Member] | Two Year Anniversary [Member]
Warrant to purchase common stock issued in period		89,002
Subsequent Event [Member] | Employees and Advisor [Member] | Stock Options [Member] | Three Year Anniversary [Member]
Warrant to purchase common stock issued in period		88,994
Subsequent Event [Member] | Minimum [Member] | Employees and Advisor [Member] | Stock Options [Member]
Warrant exercise price		$ 2.80
Subsequent Event [Member] | Maximum [Member] | Employees and Advisor [Member] | Stock Options [Member]
Warrant exercise price		$ 3.35
Subsequent Event [Member] | Notes Payable [Member]
Convertible notes payable		$ 25,000
Subsequent Event [Member] | Note [Member]
Notes payable		$ 83,333
Debt instruments interest rate		10.00%
Proceeds form issuance of notes		$ 75,000
Original issue discount		8,333
Subsequent Event [Member] | Six Months from Issuance of First Maturity Date [Member] | Convertible Notes Payable [Member]
Notes payable		$ 11,667
Debt instruments interest rate
Subsequent Event [Member] | Two Weeks Following First Maturity Date [Member] | Convertible Notes Payable [Member]
Notes payable		$ 11,667
Subsequent Event [Member] | Four Weeks Following First Maturity Date [Member] | Convertible Notes Payable [Member]
Notes payable		11,667
Subsequent Event [Member] | Six Weeks Following First Maturity Date [Member] | Convertible Notes Payable [Member]
Notes payable		11,667
Subsequent Event [Member] | Eight Weeks Following First Maturity Date [Member] | Convertible Notes Payable [Member]
Notes payable		11,667
Subsequent Event [Member] | Convertible Note One [Member]
Aggregate principal amount		120,963
Accrued interest		$ 7,006
Debt instruments conversion into shares		68,239
Subsequent Event [Member] | Convertible Note One [Member] | Minimum [Member]
Conversion price per share		$ 1.75
Subsequent Event [Member] | Convertible Note One [Member] | Maximum [Member]
Conversion price per share		$ 1.92
Subsequent Event [Member] | Notes Payable [Member] | July 1, 2017 to December 1, 2017 [Member]
Aggregate principal amount		$ 50,000
Loan, value		$ 175,000
Subsequent Event [Member] | Notes Payable [Member] | Minimum [Member] | July 1, 2017 to December 1, 2017 [Member]
Debt instruments interest rate		10.00%
Subsequent Event [Member] | Notes Payable [Member] | Maximum [Member] | July 1, 2017 to December 1, 2017 [Member]
Debt instruments interest rate		15.00%
Subsequent Event [Member] | Director and Principal [Member] | 1,75,000 Loan [Member]
Notes payable		$ 175,000
Debt instruments interest rate		15.00%
Debt instrument maturity date		Dec. 1, 2017
Subsequent Event [Member] | Lender [Member] | Notes Payable [Member]
Percentage of conversion price equal to fair market value		80.00%
Conversion price per share		$ 1
Aggregate principal amount		$ 457,250
Warrant to purchase common stock issued in period		25,000
Warrant exercise price		$ 4
Debt maturity description		maturity dates ranging from July 3, 2017 through July 4, 2017 to maturity dates ranging from October 1, 2017 through October 2, 2017.
Subsequent Event [Member] | Lender [Member] | Notes Payable [Member] | Minimum [Member]
Debt instruments interest rate		0.00%
Percentage of conversion price equal to fair market value		70.00%
Subsequent Event [Member] | Lender [Member] | Notes Payable [Member] | Maximum [Member]
Debt instruments interest rate		8.00%
Subsequent Event [Member] | Director [Member] | Notes Payable [Member] | February 2017 to February 2018 [Member]
Aggregate principal amount		$ 50,000
Warrants vested term		5 years
Warrant to purchase common stock issued in period		5,000
Warrant exercise price		$ 4
[1]	As of June 30, 2017 and December 31, 2016, a designated portion of convertible notes with an aggregate principal balance of $456,250 and $390,000, respectively, was convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $343,750 and $296,250 of principal into shares of common stock at June 30, 2017 and December 31, 2016, respectively, at the same conversion price.